Merrimack Pharmaceuticals Completes Enrollment of Second Cohort in Phase 2 Study of MM-121 in Non-Small Cell Lung Cancer
April 29, 2013 08:36 ET
|
Merrimack Pharmaceuticals
CAMBRIDGE, Mass., April 29, 2013 (GLOBE NEWSWIRE) -- Merrimack Pharmaceuticals, Inc. (Nasdaq:MACK) announced today that the last patient has been enrolled in the second cohort of a randomized,...
Merrimack Pharmaceuticals Completes Enrollment of One Cohort in Neoadjuvant Phase 2 Study of MM-121 in HER2-Negative Breast Cancer
April 15, 2013 08:00 ET
|
Merrimack Pharmaceuticals
CAMBRIDGE, Mass., April 15, 2013 (GLOBE NEWSWIRE) -- Merrimack Pharmaceuticals, Inc. (Nasdaq:MACK) announced today that the last patient has been enrolled in one group of a two-cohort randomized Phase...
Merrimack Pharmaceuticals Announces Webcast of Inaugural Research & Development Day
April 05, 2013 12:11 ET
|
Merrimack Pharmaceuticals
CAMBRIDGE, Mass., April 5, 2013 (GLOBE NEWSWIRE) -- Merrimack Pharmaceuticals, Inc. (Nasdaq:MACK) today announced that it will hold its inaugural Research & Development Day for analysts and the...
Merrimack Pharmaceuticals Completes Enrollment in a Phase 2 Study of MM-121 in Combination With Paclitaxel in Patients With Platinum-Resistant or Refractory Advanced Ovarian Cancers
March 18, 2013 08:00 ET
|
Merrimack Pharmaceuticals
CAMBRIDGE, Mass., March 18, 2013 (GLOBE NEWSWIRE) -- Merrimack Pharmaceuticals, Inc. (Nasdaq:MACK) announced today that the last patient has been enrolled in a Phase 2, open-label, randomized clinical...
Merrimack Reports Fourth Quarter and Full Year 2012 Financial Results
March 14, 2013 08:00 ET
|
Merrimack Pharmaceuticals
Enters 2013 With Six Novel Therapeutic Candidates in Clinical Development, Including Phase 3 and Phase 2 Trials in Multiple Cancer Indications
Progress Made in 2012 Puts Merrimack in Position for...
Merrimack Pharmaceuticals Announces Timing of Fourth Quarter 2012 Investor Conference Call
February 27, 2013 09:14 ET
|
Merrimack Pharmaceuticals
CAMBRIDGE, Mass., Feb. 27, 2013 (GLOBE NEWSWIRE) -- Merrimack Pharmaceuticals, Inc. (Nasdaq:MACK) today announced that the company will host its Fourth Quarter 2012 Investor Conference Call and...
Merrimack to Present at the Cowen and Company 33rd Annual Health Care Conference
February 25, 2013 12:31 ET
|
Merrimack Pharmaceuticals
CAMBRIDGE, Mass., Feb. 25, 2013 (GLOBE NEWSWIRE) -- Merrimack Pharmaceuticals, Inc. (Nasdaq:MACK) today announced that Robert Mulroy, President & CEO, is scheduled to present at the Cowen and...
Merrimack to Participate in Pancreatic Cancer Panel at the 2013 BIO CEO & Investor Conference
February 07, 2013 12:42 ET
|
Merrimack Pharmaceuticals
CAMBRIDGE, Mass., Feb. 7, 2013 (GLOBE NEWSWIRE) -- Merrimack Pharmaceuticals, Inc. (Nasdaq:MACK) today announced that Peter Laivins, Vice President of Late Stage Clinical Development and Project...
Merrimack Pharmaceuticals to Present Preclinical Data on Bispecific Antibody MM-111 in ErbB2-Positive Gastric Cancers
January 23, 2013 08:19 ET
|
Merrimack Pharmaceuticals
CAMBRIDGE, Mass., Jan. 23, 2013 (GLOBE NEWSWIRE) -- Merrimack Pharmaceuticals, Inc. (Nasdaq:MACK) announced today that preclinical data regarding the bispecific antibody MM-111 will be presented at...
Merrimack Pharmaceuticals Initiates Cross-Tumor Study to Investigate Potential Predictive Response Markers for a Developmental Nanotherapeutic Chemotherapy
December 19, 2012 14:11 ET
|
Merrimack Pharmaceuticals
CAMBRIDGE, Mass., Dec. 19, 2012 (GLOBE NEWSWIRE) -- Merrimack Pharmaceuticals, Inc. (Nasdaq:MACK) today announced enrollment of its first patient in a cross indication translational study. The study...